Home | Business News | Browse by Publication | P | PR Newswire

New Study Demonstrated Add-on Effects of ACTOS(R) (pioglitazone HCl) for Patients with Type 2 Diabetes Taking a Statin.

Article Excerpt
Conversion trial studied the effect of ACTOS on diabetic dyslipidemia compared to Avandia(R) (rosiglitazone maleate)

SAN DIEGO, June 11 /PRNewswire/ -- A new study has shown that people with type 2 diabetes on statin therapy for diabetic dyslipidemia who were switched to the oral anti-diabetic drug ACTOS from Avandia saw significant improvements, beyond those resulting from traditional cholesterol-lowering statin therapy, in key lipid parameters. These effects were independent of blood glucose control, which remained stable after the therapies were changed. The study, named COMPLEMENT, was presented today at the American Diabetes Association (ADA) 65th Annual Scientific Sessions.

"These data suggest that people with type 2 diabetes on a statin who switch from Avandia to ACTOS may realize incremental benefits to their lipid levels," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America. "Additionally, these results build on the growing body of evidence that ACTOS can confer benefits beyond blood glucose reduction: it can increase HDL and lower triglycerides. Low HDL cholesterol and elevated triglycerides represent cardiovascular risk factors for patients with type 2 diabetes."...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!